Functional 13C-urea and glucose hydrogen/methane breath tests reveal significant association of small intestinal bacterial overgrowth in individuals with active Helicobacter pylori infection

Clinical Biochemistry

Volumn 50, Issue 1-2, 2017, Pages 46-49

  Enko, Dietmar ^a,b   Kriegshäuser, Gernot ^a,b  

^a General Hospital Steyr   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Functional breath testing; Helicobacter pylori infection; Small intestinal bacterial overgrowth

Indexed keywords

GLUCOSE; METHANE; UREA;

ADULT; BREATH ANALYSIS; FEMALE; GROWTH, DEVELOPMENT AND AGING; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; SMALL INTESTINE;

ADULT; BREATH TESTS; FEMALE; GLUCOSE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTESTINE, SMALL; MALE; METHANE; MIDDLE AGED; UREA;

EID: 84994876693     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2016.08.017     Document Type: Article

References (31)

1. [1] Eusebi, L.H., Zagari, R.M., Bazzoli, F., Epidemiology of Helicobacter pylori infection. Helicobacter 19:Suppl. 1 (2014), 1–5.
2. [2] Roberts, S.E., Morrison-Rees, S., Samuel, D.G., Thorne, K., Akbari, A., Williams, J.G., Review article: the prevalence of Helicobacter pylori and the incidence of gastric cancer across Europe. Aliment. Pharmacol. Ther. 43:3 (2016), 334–345.
3. 13C urea breath test in the diagnosis of Helicobacter pylori infection. Gut 45:Suppl. 1 (1999), I18–I22.
4. [4] Williams, C.L., Preston, T., Hossack, M., Slater, C., McColl, K.E., Helicobacter pylori utilises urea for amino acid synthesis. FEMS Immunol. Med. Microbiol. 13:1 (1996), 87–94.
5. [5] Mobley, H.L., The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration. Aliment. Pharmacol. Ther. 10:Suppl. 1 (1996), 57–64.
6. [6] Kawakami, E., Machado, R.S., Reber, M., Patrício, F.R., 13C-urea breath test with infrared spectroscopy for diagnosing Helicobacter pylori infection in children and adolescents. J. Pediatr. Gastroenterol. Nutr. 35:1 (2002), 39–43.
7. [7] Marshall, B.J., Barrett, L.J., Prakash, C., McCallum, R.W., Guerrant, R.L., Urea protects Helicobacter (Campylobacter) pylori from the bactericidal effect of acid. Gastroenterology 99:3 (1990), 697–702.
8. [8] Howden, C.W., Hunt, R.H., Relationship between gastric secretion and infection. Gut 28:1 (1987), 96–107.
9. + moving through gastric mucus. Scand. J. Gastroenterol. 24:6 (1989), 761–768.
10. [10] Bures, J., Cyrany, J., Kohoutova, D., Förstl, M., Rejchrt, S., Kvetina, J., et al. Small intestinal bacterial overgrowth syndrome. World J. Gastroenterol. 16:24 (2010), 2978–2990.
11. [11] Enko, D., Kriegshäuser, G., Kimbacher, C., Stolba, R., Mangge, H., Halwachs-Baumann, G., Carbohydrate malabsorption and putative carbohydrate-specific small intestinal bacterial overgrowth: prevalence and diagnostic overlap observed in an Austrian outpatient center. Digestion 92:1 (2015), 32–38.
12. [12] Gasbarrini, A., Corazza, G.R., Gasbarrini, G., Montalto, M., Di Stefano, M., Basilisco, G., et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment. Pharmacol. Ther. 29:Suppl. 1 (2009), 1–49.
13. [13] Husebye, E., The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy 51:Suppl. 1 (2005), 1–22.
14. [14] Vesper, B.J., Jawdi, A., Altman, K.W., Haines, G.K. III, Tao, L., Radosevich, J.A., The effect of proton pump inhibitors on the human microbiota. Curr. Drug Metab. 10:1 (2009), 84–89.
15. 13C-urea breath test in Helicobacter pylori diagnosis and eradication. Correction to histology, origin of ‘false’ results, and influence of food intake. Scand. J. Gastroenterol. 32:4 (1997), 308–314.
16. 13C-urea. Aliment. Pharmacol. Ther. 16:4 (2002), 787–792.
17. [17] Burucoa, C., Delchier, J.C., Courillon-Mallet, A., de Korwin, J.D., Mégraud, F., Zerbib, F., et al. Comparative evaluation of 29 commercial Helicobacter pylori serological kits. Helicobacter 18:3 (2013), 169–179.
18. [18] Rana, S.V., Sharma, S., Kaur, J., Sinha, S.K., Singh, K., Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Digestion 85:3 (2012), 243–247.
19. [19] Holtmann, G., Goebell, H., Holtmann, M., Talley, N.J., Dyspepsia in healthy blood donors. Pattern of symptoms and association with Helicobacter pylori. Dig. Dis. Sci. 39:5 (1994), 1090–1098.
20. [20] Gray, J.D., Shiner, M., Influence of gastric pH on gastric and jejunal flora. Gut 8:6 (1967), 574–581.
21. [21] Evans, D.F., Pye, G., Bramley, R., Clark, A.G., Dyson, T.J., Hardcastle, J.D., Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 29:8 (1988), 1035–1041.
22. [22] Barer, M.R., Elliott, T.S., Berkeley, D., Thomas, J.E., Eastham, E.J., Cytopathic effects of Campylobacter pylori urease. J. Clin. Pathol., 41(5), 1988, 597.
23. [23] Smoot, D.T., Mobley, H.L., Chippendale, G.R., Lewison, J.F., Resau, J.H., Helicobacter pylori urease activity is toxic to human gastric epithelial cells. Infect. Immun. 58:6 (1990), 1992–1994.
24. [24] Mégraud, F., Neman-Simha, V., Brügmann, D., Further evidence of the toxic effect of ammonia produced by Helicobacter pylori urease on human epithelial cells. Infect. Immun. 60:5 (1992), 1858–1863.
25. [25] Suzuki, M., Miura, S., Suematsu, M., Fukumura, D., Kurose, I., Suzuki, H., et al. Helicobacter pylori-associated ammonia production enhances neutrophil-dependent gastric mucosal cell injury. Am. J. Physiol. 263:5 (1992), G719–G725.
26. [26] Marcus, E.A., Vagin, O., Tokhtaeva, E., Sachs, G., Scott, D.R., Helicobacter pylori impedes acid-induced tightening of gastric epithelial junctions. Am. J. Physiol. Gastrointest. Liver Physiol. 305:10 (2013), G731–G739.
27. [27] Sachdev, A.H., Pimentel, M., Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther. Adv. Chronic Dis. 4:5 (2013), 223–231.
28. [28] Jacobs, C., Coss Adame, E., Attaluri, A., Valestin, J., Rao, S.S., Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment. Pharmacol. Ther. 37:11 (2013), 1103–1111.
29. [29] Lombardo, L., Foti, M., Ruggia, O., Chiecchio, A., Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin. Gastroenterol. Hepatol. 8:6 (2010), 504–508.
30. [30] Jonkers, D., Houben, P., Stobberingh, E., Stockbrügger, R., Ongoing gastric acid inhibition is a confounding factor in Helicobacter pylori diagnosis. Eur. J. Gastroenterol. Hepatol. 9:1 (1997), 49–53.
31. [31] Freedberg, D.E., Lebwohl, B., Abrams, J.A., The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin. Lab. Med. 34:4 (2014), 771–785.